Sign In
Buy CLLS
$3.09
-0.290 (-8.58%)
At Close: Jun 03, 2026
Top 2 Health Care Stocks That May Keep You Up At Night This Month
08:46am, Thursday, 16'th Oct 2025
As of Oct. 16, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
07:00am, Thursday, 16'th Oct 2025
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
02:40am, Tuesday, 07'th Oct 2025
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript
11:50am, Tuesday, 05'th Aug 2025
Cellectis S.A. (NASDAQ:CLLS ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Adrian Kilcoyne - Chief Medical Officer Andre Choulika - Co-Founder, CEO & Director Arthur
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
04:30pm, Monday, 04'th Aug 2025
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
04:30pm, Monday, 28'th Jul 2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to d
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
04:30pm, Thursday, 26'th Jun 2025
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving c
Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025
04:30pm, Wednesday, 21'st May 2025
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to d
Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy
10:58am, Thursday, 15'th May 2025
Cellectis SA's pipeline consists of allogeneic CAR T-cell therapies that have the potential to make meaningful dents in heme malignancies. The financial picture remains strong, bolstered further by a
Cellectis Reports Financial Results for the First Quarter 2025
04:30pm, Monday, 12'th May 2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to d
Cellectis to Report First Quarter Financial Results on May 12, 2025
04:30pm, Tuesday, 06'th May 2025
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to de
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
04:30pm, Monday, 28'th Apr 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal
09:00am, Tuesday, 22'nd Apr 2025
Cellectis S.A. NASDAQ: CLLS is a clinical-stage biotechnology company focused on developing 'off-the-shelf' cancer immunotherapies using gene-editing technology.
Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript
10:36am, Friday, 14'th Mar 2025
Cellectis S.A. (NASDAQ:CLLS ) Q4 2024 Earnings Conference Call March 14, 2025 8:00 AM ET Company Participants Arthur Stril - CFO and Chief Business Officer Andre Choulika - CEO Adrian Kilcoyne - CMO C
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
06:07pm, Thursday, 13'th Mar 2025
○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and OD
